Breaking News

BMS Completes Sale of Couvet Site to WuXi STA

Acquisition significantly enhances WuXi STA's drug product capacity in Europe and enhances capabilities by adding capacity to support global customers.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec. The divestiture is part of Bristol Myers Squibb’s ongoing progression of its manufacturing network to support its product portfolio. Switzerland remains an important strategic location for the company, and BMS expects to maintain a strong presence in the country. The Couvet site is located in the canton of Neuchâtel, Switzerland. T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters